XML 43 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Sales of Company's products

Sales of the Company’s products were as follows:

	Three Months Ended   March 31,
($ in millions)	2017				2016
Primary Care and Women’s Health
Cardiovascular
Zetia	$	334			$	612
Vytorin	241				277
Liptruzet	49				23
Adempas	84				33
Diabetes
Januvia	839				906
Janumet	496				506
General Medicine and Women’s Health
Implanon/Nexplanon	170				134
NuvaRing	160				175
Follistim AQ	81				94
Hospital and Specialty
Hepatitis
Zepatier	378				50
HIV
Isentress	305				340
Hospital Acute Care
Bridion	148				90
Noxafil	141				145
Invanz	136				114
Cancidas	121				133
Cubicin	96				292
Primaxin	62				73
Immunology
Remicade	229				349
Simponi	184				188
Oncology
Keytruda	584				249
Emend	133				126
Temodar	66				66
Diversified Brands
Respiratory
Singulair	186				237
Nasonex	139				229
Dulera	82				113
Other
Cozaar/Hyzaar	112				126
Arcoxia	103				111
Fosamax	61				75
Vaccines (1)
Gardasil/Gardasil 9	532				378
ProQuad/M-M-R II/Varivax	355				357
RotaTeq	224				188
Pneumovax 23	163				107
Zostavax	154				125
Other pharmaceutical (2)	1,037				1,083
Total Pharmaceutical segment sales	8,185				8,104
Other segment sales (3)	1,033				905
Total segment sales	9,218				9,009
Other (4)	216				303
	$	9,434			$	9,312

⁽¹⁾  On December 31, 2016, Merck and Sanofi Pasteur terminated their equally-owned joint venture, SPMSD, which marketed vaccines in most major European markets. Accordingly, vaccine sales in 2017 include sales in the European markets that were previously part of SPMSD. Amounts for 2016 do not include sales of vaccines sold through SPMSD, the results of which are reflected in equity income from affiliates which is included in Other (income) expense, net. Amounts for 2016 do, however, include supply sales to SPMSD.

⁽²⁾  Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

⁽³⁾  Represents the non-reportable segments of Animal Health, Healthcare Services and Alliances.

⁽⁴⁾  Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first quarter of 2017 and 2016 also includes $50 million and $75 million, respectively, related to the sale of the marketing rights to certain products.

Reconciliation of segment profits to income before taxes

A reconciliation of segment profits to Income before taxes is as follows:

	Three Months Ended   March 31,
($ in millions)	2017				2016
Segment profits:
Pharmaceutical segment	$	5,180			$	5,117
Other segments	452				355
Total segment profits	5,632				5,472
Other profits	142				227
Unallocated:
Interest income	97				79
Interest expense	(182		)		(172		)
Equity income from affiliates	(12		)		20
Depreciation and amortization	(370		)		(428		)
Research and development	(1,599		)		(1,373		)
Amortization of purchase accounting adjustments	(778		)		(1,133		)
Restructuring costs	(151		)		(91		)
Other unallocated, net	(776		)		(977		)
	$	2,003			$	1,624

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration